3D printed personalized therapies for pediatric patients affected by adrenal insufficiency.

Autor:	Rodríguez-Pombo L; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain., Gallego-Fernández C; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain., Jørgensen AK; Department of Pharmaceutics, UCL School of Pharmacy, University College London, London, UK., Parramon-Teixidó CJ; Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Cañete-Ramirez C; Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Cabañas-Poy MJ; Pharmacy Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Basit AW; Department of Pharmaceutics, UCL School of Pharmacy, University College London, London, UK.; FABRX Ltd., Henwood House, Henwood, Ashford, Kent, UK.; FABRX Artificial Intelligence, Carretera de Escairón, 14, Currelos (O Saviñao), Spain., Alvarez-Lorenzo C; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain., Goyanes A; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain.; Department of Pharmaceutics, UCL School of Pharmacy, University College London, London, UK.; FABRX Ltd., Henwood House, Henwood, Ashford, Kent, UK.; FABRX Artificial Intelligence, Carretera de Escairón, 14, Currelos (O Saviñao), Spain.
Jazyk:	angličtina
Zdroj:	Expert opinion on drug delivery [Expert Opin Drug Deliv] 2024 Sep 18, pp. 1-17. Date of Electronic Publication: 2024 Sep 18.
DOI:	10.1080/17425247.2024.2399706
Abstrakt:	Background: Adrenal insufficiency is usually diagnosed in children who will need lifelong hydrocortisone therapy. However, medicines for pediatrics, in terms of dosage and acceptability, are currently unavailable. Research Design and Methods: Semi-solid extrusion (SSE) 3D printing (3DP) was utilized for manufacturing of personalized and chewable hydrocortisone formulations (printlets) for an upcoming clinical study in children at Vall d'Hebron University Hospital in Barcelona, Spain. The 3DP process was validated using a specific software for dynamic dose modulation. Results: The printlets contained doses ranging from 1 to 6 mg hydrocortisone in three different flavor and color combinations to aid adherence among the pediatric patients. The pharma-ink (mixture of drugs and excipients) was assessed for its rheological behavior to ensure reproducibility of printlets through repeated printing cycles. The printlets showed immediate hydrocortisone release and were stable for 1 month of storage, adequate for prescribing instructions during the clinical trial. Conclusions: The results confirm the suitability and safety of the developed printlets for use in the clinical trial. The required technical information from The Spanish Medicines Agency for this clinical trial application was compiled to serve as guidelines for healthcare professionals seeking to apply for and conduct clinical trials on 3DP oral dosage forms.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu